SynBioBeta: Antheia Raises $56M Series C to Alleviate Global Drug Shortages with Synthetic Biology

Antheia has raised $56 million in a Series C financing round to accelerate its synthetic biology platform, which harnesses engineered yeast to produce essential pharmaceutical ingredients in weeks instead of years, positioning the company to tackle chronic global drug shortages.
San Francisco Business Times: Daily Digest: Billionaire’s SFPD tech overhaul plan, Salesforce bolsters AI staff

Menlo Park-based Narcan ingredient maker Antheia raised $56 million in Series C funding.
FinSMEs: Antheia Raises $56M in Series C Funding

Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $56M in Series C funding.
Axios: Narcan ingredient maker Antheia raises $56M to expand platform

Antheia, manufacturer of a major Narcan ingredient, raised a $56 million Series C round, co-founder and CEO, Christina Smolke, tells Axios.
Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy

New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform.
Celebrating Antheia’s Series C Financing

After a busy year marked by major commercial milestones for Antheia, we are excited to announce $56 million in Series C financing. With the support of new and existing investors, we are entering a new chapter as a business, bringing us closer than ever to a world without essential medicine shortages.